ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VMD / dividends
PARK (60) AGL (36) PGNY (79) CCEL (70) ⌘ Pro Terminal →

Viemed Healthcare Inc. (VMD) Dividend Safety Gauge & 10-Year DRIP Compounder

$9.44 -2.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.42

Viemed Healthcare Inc. (VMD) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (57.5% gross margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $368.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $9.44 (-2.38% 1D, market cap $368.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, VMD ranks #63 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VMD compare to PARK and AGL in the Health Care sector?
▼

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (72/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and AGL (agilon health inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VMD?
▼

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (57.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.42 (-0.19%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Cash (16)Whales (9)SEC (18)Macro (14)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+6.2% Base Target
$13 Bull$10 Base$8 Bear
📬 FREE VMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VMD)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY VMD SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
80
Grade A-$9.61+2% Next Q
Q2 (-2Q)
77
Grade B+$9.80-1.2% Next Q
Q3 (-1Q)
75
Grade B+$9.68-2.5% Next Q
Current
72
Grade B$9.44+7% Hist 90D α
Trajectory: A- (80) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.26) or 200D SMA ($9.59) invalidates the momentum regime and cuts Target Base ($10.03) toward Bear Floor ($7.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (13.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $34,247

Est. Year-10 Shareholder Yield: $616/yr
$11.3K
Yr 1
$12.8K
Yr 2
$14.5K
Yr 3
$16.4K
Yr 4
$18.5K
Yr 5
$20.9K
Yr 6
$23.7K
Yr 7
$26.8K
Yr 8
$30.3K
Yr 9
$34.2K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in VMD & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on VMD and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.42%▲ ASCENDING CHANNEL
2026-11-03O $9.95H $9.95L $9.44C $9.44VOL 119.5K
RES: $10.26SUP: $8.63SMA50: $9.26SMA200: $9.59
$12.96$11.51$10.05$8.60$7.15RES $10.26SUP $8.63$9.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VMD Butterfly Map → + Track VMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
18.3%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VMD)

Health Care Rank #63 of 1015 ⚔️ PARK vs VMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VMD vs. PARK, AGL, PGNY, CCEL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #63 by composite RQD confidence (72/100, grade B) and #488 by equity capitalization ($368.3M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with VMD at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VMD ACTIVE
Viemed Healthcare Inc.
B 72/100 24.6x 57.5% 13.0% -2.38% $368.3M Benchmark Subject
PARK
Park Dental Partners Inc.
C- 60/100 — — — -2.09% $100.3M /park-vs-vmd →
AGL
agilon health inc.
D- 36/100 — — -35.0% +2.04% $1.43B /agl-vs-vmd →
PGNY
Progyny Inc.
B+ 79/100 37.2x 23.6% 16.7% +0.75% $2.24B /pgny-vs-vmd →
CCEL
Cryo-Cell International Inc.
B- 70/100 — — 18.2% +2.69% $42.0M /ccel-vs-vmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729149 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $270.3M $15.4M $51.9M $11.9M $199.2M $11.3M
FY2024 (FY) 2024-12-31 $224.3M $11.4M $39.1M $1.3M $177.1M $3.6M
FY2023 (FY) 2023-12-31 $183.0M $10.2M $45.2M $45.2M — —

3. VMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $9.44 (-2.38% 1D, market cap $368.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, VMD ranks #63 in composite RQD confidence.

How does VMD compare to PARK and AGL in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (72/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and AGL (agilon health inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VMD?

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (57.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VMD trading relative to its 50-day, 200-day, and 52-week technical levels?

VMD last traded at $9.44 (-2.38% on volume of 226,701 shares), positioning the stock +1.94% above its 50-day simple moving average ($9.26) and -1.56% below its 200-day simple moving average ($9.59). Across its 52-week range of $6.05 to $12.61, VMD sits at the 51.7% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($8.90 to $9.98).

Direct Sub-Reports: VMD RQD Cockpit VMD 12M Forecast VMD Earnings & Move VMD Dividends & DRIP VMD Insiders & 13F VMD Whale Options VMD Profit Sankey VMD News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

VMD — Viemed Healthcare Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Viemed Healthcare Inc. (VMD) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $9.44 (-2.38% 1D, market capitalization $368.3M).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 13.0%, gross margin of 57.5%, operating margin of 8.5%, and free cash flow yield of 3.15%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 6.59, Piotroski F-Score of 9/9, and Debt/Equity of 0.08x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Viemed Healthcare Inc. (VMD) is listed on NASDAQ in the Health Care sector, Misc Health and Biotechnology Services industry. The profile describes it as a NASDAQ-listed Health Care issuer with a market capitalization of $0.4B. Recent headlines reference home respiratory care, sleep, and maternal health, per the news section, but this is headline-level only.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported $270.3M in annual revenue (up from $224.3M in FY2024, +20.5% YoY) and $15.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($183.0M revenue, $10.2M net income) through FY2025, VMD scaled operating cash flow to $51.9M and free cash flow to $11.9M, backed by $199.2M in total assets against $11.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (57.5% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $6.05 – $12.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 24.6x trailing P/E and 6.6x EV/EBITDA against 8.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— (The Butterfly Supply-Chain Graph reports supply_chain "NONE" with no links.)

  • Key Question #1: Can VMD sustain or expand its 8.5% operating margin and 13.0% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $270.3M and free cash flow of $11.9M, how will capital allocation balance growth reinvestment against $11.3M in total debt?
  • Key Question #3: How sensitive is VMD's 20.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viemed Healthcare Inc. (VMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VMD Bull vs. Bear Conversation Board — What's Your Call at $9.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $11.31 (+17.0%)
📌 Pinned Debate

Per the RQD rating, the forensic balance sheet scores 18/20 with Altman Z 6.59, Piotroski F 9/9, and Debt/Equity 0.08, alongside 13% RO

The street is overcomplicating Viemed Healthcare Inc. (VMD). Per the RQD rating, the forensic balance sheet scores 18/20 with Altman Z 6.59, Piotroski F 9/9, and Debt/Equity 0.08, alongside 13% ROIC.. With an RQD score of 72/100 (B) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $10.44.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 24.6x trailing P/E, but you're ignoring the forward operating leverage in Misc Health and Biotechnology Services. If gross margin (57.5%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $8.32 (-14.0%)
Spot @ $9.67

Trailing P/E of 24.6 against a 3.15% FCF yield leaves valuation dependent on sustained earnings growth, while whale-flow and insider pi

I respect the product at Viemed Healthcare Inc., but the stock at $9.67 is a different story. Trailing P/E of 24.6 against a 3.15% FCF yield leaves valuation dependent on sustained earnings growth, while whale-flow and insider pillars rest on unitemized data.. FCF yield is 3.15% and RQD sits at 72/100 (B) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%